AZURE SHELTON: Open Payments
NPI 1588419980 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,429 in 116 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $1,110 · 2025 $2,429
Food & beverage: $2,429
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $439 |
| Janssen Pharmaceuticals, Inc | 8 | $393 |
| Vanda Pharmaceuticals Inc. | 20 | $337 |
| ABBVIE INC. | 23 | $241 |
| E.R. Squibb & Sons, L.L.C. | 7 | $234 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $212 |
| Axsome Therapeutics, Inc. | 6 | $157 |
| Alkermes, Inc. | 12 | $140 |
| Biogen, Inc. | 6 | $123 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
Products named: REXULTI, INVEGA SUSTENNA, VRAYLAR, COBENFY, HETLIOZ, CAPLYTA, Auvelity, SPRAVATO.
Industry payments across KY — which companies pay providers there.
